Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study.

@article{Read2004PhaseIS,
  title={Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study.},
  author={William J. L. Read and L Toles and Edie Romvari and D. Adkins and Ping Liao and Ramaswamy Govindan},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7364}
}
7364 Background: The outcomes for patients with metastatic lung cancer are dismal, with one-year survival rates of approximately 35%. We are evaluating the combination of irinotecan (I) and carboplatin (C) in patients with stage IIIB and IV non-small cell lung cancer. A preliminary report of this study was presented earlier (ASCO 2003, A 2704) Methods: Eligible patients include those with histological or cytological diagnosis of non-small cell lung cancer, no previous chemotherapy for… CONTINUE READING